FTC’s Androgel Case May Not Be Best To Tackle Pay-For-Delay

Law360, New York (October 5, 2012, 9:09 PM EDT) -- The Federal Trade Commission has argued that its case over the legality of pay-for-delay settlements involving blockbuster drug Androgel is a strong candidate for high court review, but with two other petitions already pending before the justices in a separate case over the controversial patent deals, attorneys on Friday questioned the agency's position.

The FTC was the third party to seek certiorari over pay-for-delay after a pair of petitions from the defendants in a Third Circuit case over the drug K-Dur 20, which endorsed the FTC's...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.